Copyright
©2014 Baishideng Publishing Group Co.
World J Gastroenterol. May 7, 2014; 20(17): 5031-5035
Published online May 7, 2014. doi: 10.3748/wjg.v20.i17.5031
Published online May 7, 2014. doi: 10.3748/wjg.v20.i17.5031
Table 2 Serum infliximab and antibody levels in cases of antibody positivity
| Patients | Serum IFX level (μg/mL) | ATI level (μg/mL) |
| 1 | 2.75 | 3194.90 |
| 2 | 2.68 | 258.55 |
| 3 | 2.67 | 1056.25 |
| 4 | 2.66 | 3055.04 |
| 5 | 2.93 | 3712.82 |
| 6 | 2.26 | 3343.07 |
| 7 | 2.66 | 129.54 |
| 8 | 2.49 | 4540.33 |
| 9 | 12.40 | 58.92 |
| 10 | 2.66 | 3679.21 |
| 11 | 2.65 | 536.57 |
| 12 | 1.90 | 555.53 |
| 13 | 1.71 | 810.87 |
| 14 | 4.67 | 46.34 |
- Citation: Pallagi-Kunstár &, Farkas K, Szepes Z, Nagy F, Szűcs M, Kui R, Gyulai R, Bálint A, Wittmann T, Molnár T. Utility of serum TNF-α, infliximab trough level, and antibody titers in inflammatory bowel disease. World J Gastroenterol 2014; 20(17): 5031-5035
- URL: https://www.wjgnet.com/1007-9327/full/v20/i17/5031.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i17.5031